Literature DB >> 27644933

Prostate cancer: HSD3B1 variant confers inferior ADT outcomes.

Peter Sidaway.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27644933     DOI: 10.1038/nrurol.2016.183

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN: 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  1 in total

1.  HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study.

Authors:  Jason W D Hearn; Ghada AbuAli; Chad A Reichard; Chandana A Reddy; Cristina Magi-Galluzzi; Kai-Hsiung Chang; Rachel Carlson; Laureano Rangel; Kevin Reagan; Brian J Davis; R Jeffrey Karnes; Manish Kohli; Donald Tindall; Eric A Klein; Nima Sharifi
Journal:  Lancet Oncol       Date:  2016-08-27       Impact factor: 41.316

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.